On the lookout for potential new medical cannabis patients, Canopy Growth Corporation (TSX: WEED; NYSE: CGC) today announced a partnership with the Arthritis Society through medical subsidiary Spectrum Cannabis.
Through the newly announced affiliation, Spectrum will host a series of talks about arthritis and the potential use of cannabis to treat the symptoms of the disease. In addition to those in-person symposiums currently being lined up around Canada, Spectrum and the Arthritis Society are currently crafting online education materials to be made available globally.
The Arthritis Society’s Chief Science Officer, Dr. Siân Bevan, stated those materials will offer evidence-based information for patients to discuss with their medical professional for making decisions on possible treatment through cannabis usage.
Discussing the new partnership, Canopy Growth’s Chief Medical Officer Dr. Mark Ware commented:
According to the Arthritis Society, more than 6 million Canadians are currently living with arthritis. The organization will raise funds into researching the disease with the 10th annual Walk For Arthritis on June 1 with walkers raising pledges for 1km and 5km routes.
In addition to this focus on acquiring new medical patients in Canada, Canopy also recently expanded into UK medical operations.
Earlier this year, the company announced the formation of a joint UK venture with Beckley Canopy Therapeutics to be named Spectrum Biomedical UK. The joint company is focused both on education initiatives to increase awareness about medical cannabis usage, as well as commercially providing cannabis products to patients.
That isn’t the only outreach initiative launched by Canopy in recent months, with the company appointing noted patient advocacy figure Hilary Black to a position in senior management.
In other major company news, Canopy is gearing up to enter the U.S. recreational cannabis market after confirming plans to acquire multi-state operator Acreage Holdings, Inc. (CSE: ACGR.U; OTC: ACRGF; FSE: 0ZV). The terms of that estimated $3.1 billion deal include a provision that the buyout will occur after marijuana usage is legalized at the federal level in the U.S.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.